

1 IRELL & MANELLA LLP
Alexander F. Wiles (CA 73596) awiles@irell.com
2 Brian Hennigan (CA 86955) bhennigan@irell.com
Trevor V. Stockinger (CA 226359) tstockinger@irell.com
3 S. Albert Wang (CA 250163) awang@irell.com
1800 Avenue of the Stars, Suite 900
4 Los Angeles, California 90067-4276
Telephone: (310) 277-1010
5 Facsimile: (310) 203-7199

6 ARNOLD & PORTER LLP
Kenneth A. Letzler (*Admitted Pro Hac Vice*) Kenneth_Letzler@aporter.com
7 Daniel S. Pariser (*Admitted Pro Hac Vice*) Daniel_Pariser@aporter.com
555 Twelfth Street, NW
8 Washington, DC 20004-1206
Telephone: (202) 942-5000
9 Facsimile: (202) 942-5999

10 *Attorneys for Plaintiff GlaxoSmithKline*

11
12 **UNITED STATES DISTRICT COURT**
13 **NORTHERN DISTRICT OF CALIFORNIA**
14 **OAKLAND DIVISION**

15 SMITHKLINE BEECHAM CORPORATION
16 d/b/a GLAXOSMITHKLINE,

17 Plaintiff,

18 v.

19 ABBOTT LABORATORIES,

20 Defendant.

Case No. C 07-5702 (CW)

**ADMINISTRATIVE MOTION TO
FILE UNDER SEAL DOCUMENTS
SUPPORTING GSK'S RESPONSE TO
ABBOTT'S SUPPLEMENTAL BRIEF
IN SUPPORT OF ABBOTT
LABORATORIES' MOTION FOR
SUMMARY JUDGMENT ON GSK'S
FIRST AMENDED COMPLAINT
(LOCAL RULES 79-5 AND 7-11)**

21
22 Date: October 28, 2010
Time: 2:00 p.m.
23 Courtroom: 2 (4th Floor)
Judge: Hon. Claudia Wilken
24

NOTICE OF MOTION

PLEASE TAKE NOTICE that plaintiff SmithKline Beecham Corporation d/b/a GlaxoSmithKline (“GSK”) hereby moves pursuant to Local Rules 79-5 and 7-11 for Administrative Relief to file the following materials, or portions there of, under seal:

1. Exhibits 1 and 3 to the Declaration of S. Albert Wang in Support of GSK's Response to Abbott's Supplemental Brief in Support of Abbott Laboratories' Motion for Summary Judgment on GSK's First Amended Complaint (“Wang Declaration”).

2. Portions of GSK’s Response to Abbott’s Supplemental Brief in Support of Abbott Laboratories' Motion for Summary Judgment on GSK’s First Amended Complaint (“GSK's Response”) that rely on Exhibit 1 to the Wang Declaration.

3. Portions of GSK's Response that rely on documents designated confidential by Abbott and ordered to be filed under seal pursuant to Order re GSK's Miscellaneous Administrative Motion to File Under Seal. (Docket # 268.)

This motion is brought because the relevant materials have been designated as “Highly Confidential – Attorneys' Eyes Only” or rely on materials designated “Highly Confidential – Attorneys' Eyes Only” by defendant Abbott Laboratories (“Abbott”). In accordance with this Court’s March 24, 2008 Order, GSK conferred with Abbott about confidentiality designations of the documents anticipated to be cited in support of GSK’s Response. *Ow Decl.* ¶ 2. Abbott did not withdraw any of its confidentiality designations. *Id.*

Dated: November 11, 2010

Respectfully submitted,

IRELL & MANELLA LLP

By: s/ Trevor Stockinger
Trevor V. Stockinger

Counsel for GSK